Vir Biotechnology VIR
NASDAQ VIR
$13.15 -0.50 (-3.66%)
At close: Nov 10, 2026 · 4:00 PM EST

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Updated

Vir Biotechnology (VIR) reported Preferred Stock Liabilities of $636.61 million for Q3 2019, up 105.9% from $309.14 million a year earlier and unchanged from the prior quarter.

Analysis

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

At the end of FY2018, Vir Biotechnology posted Preferred Stock Liabilities of $309.14 million, up 5.7% from FY2017.

  • By year, Preferred Stock Liabilities came in at $292.53 million in FY2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Vir Biotechnology 2.28 Bn 363.84 Mn 188,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 636.61 Mn
Jun 30, 2019 636.61 Mn
Dec 31, 2018 309.14 Mn
Sep 30, 2018 309.14 Mn
API Access

Vir Biotechnology Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=VIR&period=max&api_key=YOUR_API_KEY